Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Genetics of the hemophilias

W Keith Hoots, MD
Amy D Shapiro, MD
Section Editors
Lawrence LK Leung, MD
Donald H Mahoney, Jr, MD
Benjamin A Raby, MD, MPH
Deputy Editor
Jennifer S Tirnauer, MD


The hemophilias are a group of related bleeding disorders that usually are inherited. Inherited bleeding disorders include abnormalities of coagulation factors as well as platelet function, the most common of which is von Willebrand disease. However, when the term "hemophilia" is used, it usually refers specifically to the following two disorders:

Factor VIII deficiency (hemophilia A) – Hemophilia A affects 1 in 5000 to 10,000 males; roughly 60 percent have severe disease, with factor VIII activity less than 1 percent of normal.

Factor IX deficiency (hemophilia B) – Hemophilia B affects 1 in 25,000 to 30,000 males; approximately one-half have mild to moderate disease, with factor IX activity greater than 1 percent of normal.

Severe factor VIII or factor IX deficiency leads to bleeding because of the role these factors play in the intrinsic pathway X-ase (ten-ase). The X-ase complex consists of activated factor IX (factor IXa) as the protease; activated factor VIII (factor VIIIa), calcium, and phospholipids as the cofactors; and factor X as the substrate (figure 1) [1]. (See "Overview of hemostasis", section on 'Multicomponent complexes' and "Biology and normal function of factor VIII and factor IX".)

This topic reviews the genetic basis of Hemophilia A and B. Diagnosis and management of patients with hemophilia are discussed separately.


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Aug 2, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Brandstetter H, Bauer M, Huber R, et al. X-ray structure of clotting factor IXa: active site and module structure related to Xase activity and hemophilia B. Proc Natl Acad Sci U S A 1995; 92:9796.
  2. Hoyer LW. Hemophilia A. N Engl J Med 1994; 330:38.
  3. MERSKEY C. The occurrence of haemophilia in the human female. Q J Med 1951; 20:299.
  4. Panarello C, Acquila M, Caprino D, et al. Concomitant Turner syndrome and hemophilia A in a female with an idic(X)(p11) heterozygous at locus DXS52. Cytogenet Cell Genet 1992; 59:241.
  5. Pavlova A, Brondke H, Müsebeck J, et al. Molecular mechanisms underlying hemophilia A phenotype in seven females. J Thromb Haemost 2009; 7:976.
  6. Valleix S, Vinciguerra C, Lavergne JM, et al. Skewed X-chromosome inactivation in monochorionic diamniotic twin sisters results in severe and mild hemophilia A. Blood 2002; 100:3034.
  7. Lawn RM. The molecular genetics of hemophilia: blood clotting factors VIII and IX. Cell 1985; 42:405.
  8. Leuer M, Oldenburg J, Lavergne JM, et al. Somatic mosaicism in hemophilia A: a fairly common event. Am J Hum Genet 2001; 69:75.
  9. Costa C, Frances AM, Letourneau S, et al. Mosaicism in men in hemophilia: is it exceptional? Impact on genetic counselling. J Thromb Haemost 2009; 7:367.
  10. Gitschier J, Wood WI, Goralka TM, et al. Characterization of the human factor VIII gene. Nature 1984; 312:326.
  11. Wood WI, Capon DJ, Simonsen CC, et al. Expression of active human factor VIII from recombinant DNA clones. Nature 1984; 312:330.
  12. Vehar GA, Keyt B, Eaton D, et al. Structure of human factor VIII. Nature 1984; 312:337.
  13. Toole JJ, Knopf JL, Wozney JM, et al. Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 1984; 312:342.
  14. Goodeve AC. Hemophilia B: molecular pathogenesis and mutation analysis. J Thromb Haemost 2015; 13:1184.
  15. Edison E, Konkle BA, Goodeve AC. Genetic analysis of bleeding disorders. Haemophilia 2016; 22 Suppl 5:79.
  16. Li JN, Carrero IG, Dong JF, Yu FL. Complexity and diversity of F8 genetic variations in the 1000 genomes. J Thromb Haemost 2015; 13:2031.
  17. Bach JE, Wolf B, Oldenburg J, et al. Identification of deep intronic variants in 15 haemophilia A patients by next generation sequencing of the whole factor VIII gene. Thromb Haemost 2015; 114:757.
  18. Lawn RM, Vehar GA. The molecular genetics of hemophilia. Sci Am 1986; 254:48.
  19. Tuddenham EG, Schwaab R, Seehafer J, et al. Haemophilia A: database of nucleotide substitutions, deletions, insertions and rearrangements of the factor VIII gene, second edition. Nucleic Acids Res 1994; 22:4851.
  20. Antonarakis SE, Rossiter JP, Young M, et al. Factor VIII gene inversions in severe hemophilia A: results of an international consortium study. Blood 1995; 86:2206.
  21. Amano K, Sarkar R, Pemberton S, et al. The molecular basis for cross-reacting material-positive hemophilia A due to missense mutations within the A2-domain of factor VIII. Blood 1998; 91:538.
  22. Cunningham MA, Pipe SW, Zhang B, et al. LMAN1 is a molecular chaperone for the secretion of coagulation factor VIII. J Thromb Haemost 2003; 1:2360.
  23. Neerman-Arbez M, Johnson KM, Morris MA, et al. Molecular analysis of the ERGIC-53 gene in 35 families with combined factor V-factor VIII deficiency. Blood 1999; 93:2253.
  24. Zhang B, Cunningham MA, Nichols WC, et al. Bleeding due to disruption of a cargo-specific ER-to-Golgi transport complex. Nat Genet 2003; 34:220.
  25. Lillicrap D. The molecular basis of haemophilia B. Haemophilia 1998; 4:350.
  26. Taylor SA, Duffin J, Cameron C, et al. Characterization of the original Christmas disease mutation (cysteine 206----serine): from clinical recognition to molecular pathogenesis. Thromb Haemost 1992; 67:63.
  27. Attali O, Vinciguerra C, Trzeciak MC, et al. Factor IX gene analysis in 70 unrelated patients with haemophilia B: description of 13 new mutations. Thromb Haemost 1999; 82:1437.
  28. Giannelli F, Green PM, Sommer SS, et al. Haemophilia B: database of point mutations and short additions and deletions--eighth edition. Nucleic Acids Res 1998; 26:265.
  29. Veltkamp JJ, Meilof J, Remmelts HG, et al. Another genetic variant of haemophilia B: haemophilia B Leyden. Scand J Haematol 1970; 7:82.
  30. Briët E, Bertina RM, van Tilburg NH, Veltkamp JJ. Hemophilia B Leyden: a sex-linked hereditary disorder that improves after puberty. N Engl J Med 1982; 306:788.
  31. Reijnen MJ, Peerlinck K, Maasdam D, et al. Hemophilia B Leyden: substitution of thymine for guanine at position -21 results in a disruption of a hepatocyte nuclear factor 4 binding site in the factor IX promoter. Blood 1993; 82:151.
  32. Picketts DJ, Mueller CR, Lillicrap D. Transcriptional control of the factor IX gene: analysis of five cis-acting elements and the deleterious effects of naturally occurring hemophilia B Leyden mutations. Blood 1994; 84:2992.
  33. Hildyard C, Keeling D. Effect of age on factor IX levels in symptomatic carriers of Haemophila B Leyden. Br J Haematol 2015; 169:448.
  34. Kurachi S, Huo JS, Ameri A, et al. An age-related homeostasis mechanism is essential for spontaneous amelioration of hemophilia B Leyden. Proc Natl Acad Sci U S A 2009; 106:7921.
  35. Rimmer EK, Seftel MD, Israels SJ, Houston DS. Unintended benefit of anabolic steroid use in hemophilia B leiden. Am J Hematol 2012; 87:122.
  36. Crossley M, Ludwig M, Stowell KM, et al. Recovery from hemophilia B Leyden: an androgen-responsive element in the factor IX promoter. Science 1992; 257:377.
  37. Diuguid DL, Rabiet MJ, Furie BC, et al. Molecular basis of hemophilia B: a defective enzyme due to an unprocessed propeptide is caused by a point mutation in the factor IX precursor. Proc Natl Acad Sci U S A 1986; 83:5803.
  38. Bentley AK, Rees DJ, Rizza C, Brownlee GG. Defective propeptide processing of blood clotting factor IX caused by mutation of arginine to glutamine at position -4. Cell 1986; 45:343.
  39. Noyes CM, Griffith MJ, Roberts HR, Lundblad RL. Identification of the molecular defect in factor IX Chapel Hill: substitution of histidine for arginine at position 145. Proc Natl Acad Sci U S A 1983; 80:4200.
  40. Geddes VA, Le Bonniec BF, Louie GV, et al. A moderate form of hemophilia B is caused by a novel mutation in the protease domain of factor IXVancouver. J Biol Chem 1989; 264:4689.
  41. Taylor SA, Liddell MB, Peake IR, et al. A mutation adjacent to the beta cleavage site of factor IX (valine 182 to leucine) results in mild haemophilia Bm. Br J Haematol 1990; 75:217.
  42. Hamaguchi N, Roberts H, Stafford DW. Mutations in the catalytic domain of factor IX that are related to the subclass hemophilia Bm. Biochemistry 1993; 32:6324.